Benson C, Miah AB. Uterine sarcoma—current perspectives. Int J Womens Health. 2017;31(9):597–606. https://doi.org/10.2147/IJWH.S117754.

Google Scholar 

Mbatani N, Olawaiye AB, Prat J. Uterine sarcomas. Int J Gynecol Obstet. 2018. https://doi.org/10.1002/ijgo.12613.

Google Scholar 

Kostov S, Kornovski Y, Ivanova V, Dzhenkov D, Metodiev D, Watrowski R, Ivanova Y, Slavchev S, Mitev D, Yordanov A. New aspects of sarcomas of uterine corpus—a brief narrative review. Clin Pract. 2021;11(4):878–900. https://doi.org/10.3390/clinpract11040103.

PubMed  PubMed Central  Google Scholar 

Mocellin S. A practical and comprehensive guide to sarcomas and benign neoplasms. 1st ed. Berlin: Springer; 2021.

Google Scholar 

Shushkevich A, Thaker PH, Littell RD, Shah NA, Chiang S, Thornton K, Hensley ML, Slomovitz BM, Holcomb KM, Leitao MM, et al. State of the science: uterine sarcomas: from pathology to practice. Gynecol Oncol. 2020;159:3–7. https://doi.org/10.1016/j.ygyno.2020.08.008.

PubMed  Google Scholar 

Brohl AS, Li L, Andikyan V, Običan SG, Cioffi A, Hao K, Dudley JT, Ascher-Walsh C, Kasarskis A, Maki RG. Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma. Oncologist. 2015;20(4):433–9. https://doi.org/10.1634/theoncologist.2014-0361.

PubMed  PubMed Central  Google Scholar 

Chantasartrassamee P, Kongsawatvorakul C, Rermluk N, Charakorn C, Wattanayingcharoenchai R, Lertkhachonsuk AA. Preoperative clinical characteristics between uterine sarcoma and leiomyoma in patients with uterine mass, a case-control study. Eur J Obstet Gynecol Reprod Biol. 2022;270:176–80.

PubMed  Google Scholar 

Liu J, Wang Z. Advances in the preoperative identification of uterine sarcoma. Cancers. 2022;14:3517. https://doi.org/10.3390/cancers14143517.

CAS  PubMed  PubMed Central  Google Scholar 

Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: an analysis of 26,758 cases. Int J Cancer. 2006;119:2922–30.

CAS  PubMed  Google Scholar 

Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol. 2004;93:204–8.

PubMed  Google Scholar 

Tropé CG, Abeler VM, Kristensen GB. Diagnosis and treatment of sarcoma of the uterus. A review, Acta Oncologica. 2012;51(6):694–705. https://doi.org/10.3109/0284186X.2012.689111.

PubMed  Google Scholar 

Mark RJ, Poen J, Tran LM, Fu YS, Heaps J, Parker RG. Postirradiation sarcoma of the gynecologic tract. A report of 13 cases and a discussion of the risk of radiation-induced gynecologic malignancies. Am J Clin Oncol. 1996;19:59–64.

CAS  PubMed  Google Scholar 

Yildirim Y, Inal MM, Sanci M, Yildirim YK, Mit T, Polat M, Tinar S. Development of uterine sarcoma after tamoxifen treatment for breast cancer: report of four cases. Int J Gynecol Cancer. 2005;15:1239–42. https://doi.org/10.1111/j.1525-1438.2005.00170.x.

CAS  PubMed  Google Scholar 

Zeng C, Du S, Han Y, Fu J, Luo Q, Xiang Y, Chen X, Luo T, Li Y, Zheng Y. Optic radiations are thinner and show signs of iron deposition in patients with long-standing remitting-relapsing multiple sclerosis: an enhanced T(2)(*)-weighted angiography imaging study. Eur Radiol. 2018;28:4447–54.

PubMed  PubMed Central  Google Scholar 

Khan SR, Soomar SM, Asghari T, et al. Prognostic factors, oncological treatment and outcomes of uterine sarcoma: 10 years’ clinical experience from a tertiary care center in Pakistan. BMC Cancer. 2023;23:510. https://doi.org/10.1186/s12885-023-11000-3.

CAS  PubMed  PubMed Central  Google Scholar 

Lavie O, Barnett-Griness O, Narod SA, et al. The risk of developing uterine sarcoma after tamoxifen use. Int J Gynecol Cancer. 2008;18:352–6.

CAS  PubMed  Google Scholar 

Preoperative clinical characteristics between uterine sarcoma and leiomyoma in patients with uterine mass, a case-control study. https://www.sciencedirect.com/journal/european-journal-of-obstetrics-and-gynecology-and-reproductive-biology.

Pérez-Fidalgo JA, Ortega E, Ponce J, Redondo A, Sevilla I, Valverde C, IsernVerdum J, De Álava E, GaleraLópez M, Marquina G, Sebio A. Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS). Ther Adv Med Oncol. 2023;15:17588359231157644.

PubMed  PubMed Central  Google Scholar 

Pérez-Fidalgo JA, Ortega E, Ponce J, Redondo A, Sevilla I, Valverde C, IsernVerdum J, De Álava E, GaleraLópez M, Marquina G, Sebio A. Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS). Ther Adv Med Oncol. 2023;15:1–19.

Google Scholar 

Giunchi S, Perrone AM, Tesei M, Bovicelli A, De Crescenzo E, Dondi G, Boussedra S, Di Stanislao M, De Iaco P. Sonographic imaging in uterine sarcoma: a narrative review of literature. Gynecol Pelvic Med. 2022;5:14.

Google Scholar 

Toyohara Y, Sone K, Noda K, et al. Development of a deep learning method for improving diagnostic accuracy for uterine sarcoma cases. Sci Rep. 2022;12:19612. https://doi.org/10.1038/s41598-022-23064-5.

CAS  PubMed  PubMed Central  Google Scholar 

Hélage S, Vandeventer S, Buy J-N, Bordonné C, Just P-A, Jacob D, Ghossain M, Rousset P, Dion É. Uterine sarcomas: Are there MRI signs predictive of histopathological diagnosis? A 50-patient case series with pathological correlation. Sarcoma. 2021;2021:8880080. https://doi.org/10.1155/2021/8880080.

PubMed  PubMed Central  Google Scholar 

Malek M, Gity M, Alidoosti A, Oghabian Z, Rahimifar P, Ebrahimi SMS, Tabibian E, Oghabian MA. A machine learning approach for distinguishing uterine sarcoma from leiomyomas based on perfusion weighted MRI parameters. Eur J Radiol. 2019;110:203–11.

PubMed  Google Scholar 

Rahimifar P, Hashemi H, Malek M, Ebrahimi S, Tabibian E, Alidoosti A, Mousavi A, Yarandi F. Diagnostic value of 3 T MR spectroscopy, diffusion-weighted MRI, and apparent diffusion coefficient value for distinguishing benign from malignant myometrial tumours. Clin Radiol. 2019;74(571):e9-571.e18.

Google Scholar 

Takeuchi M, Matsuzaki K, Harada M. Clinical utility of susceptibility-weighted MR sequence for the evaluation of uterine sarcomas. Clin Imaging. 2019;53:143–50.

PubMed  Google Scholar 

Tian S, Liu A, Chen A, Niu M, Wei Q. Differential diagnosis of uterine sarcoma and degenerative hysteromyoma by using multiple quantitative parameters of enhanced T2 star weighted angiography. Chin J Med Imaging. 2020;28:108–11.

Google Scholar 

Sahdev A, Sohaib SA, Jacobs I, Shepherd JH, Oram DH, Reznek RH. MR imaging of uterine sarcomas. Am J Roentgenol. 2001;177(6):1307–11.

CAS  Google Scholar 

Camponovo C, Neumann S, Zosso L, Mueller MD, Raio L. Sonographic and magnetic resonance characteristics of gynecological sarcoma. Diagnostics. 2023;13(7):1223.

CAS  PubMed  PubMed Central  Google Scholar 

Li K, Yin R, Li L, Wang D, Li L, Ma C, Ren Q, Wang G, Fan Y, Zhou H, Liu Z, Li T, Luo K, Kui D, Wang J. Diagnosis and treatment of uterine sarcoma: a multicenter, real-world study in western China. Medicine (Baltimore). 2021;100(51):e28220. https://doi.org/10.1097/MD.0000000000028220.

CAS  PubMed  Google Scholar 

Stukan M, Rutkowski P, Smadja J, Bonvalot S. Ultrasound-guided trans-uterine cavity core needle biopsy of uterine myometrial tumors to differentiate sarcoma from a benign lesion-description of the method and review of the literature. Diagnostics (Basel). 2022;12(6):1348. https://doi.org/10.3390/diagnostics12061348.

CAS  PubMed  Google Scholar 

Barrek and hackers text book reference.

Leitao MM Jr, Zivanovic O, Chi DS, et al. Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis. Gynecol Oncol. 2012;125:409–13. https://doi.org/10.1016/j.ygyno.2012.02.014

PubMed  Google Scholar 

Giannini A, D’Augè TG, Bogani G, Laganà AS, Chiantera V, Vizza E, Muzii L, Di Donato V. Uterine sarcomas: a critical review of the literature. Eur J Obstet Gynecol Reprod Biol. 2023;287:166–70.

PubMed  Google Scholar 

Harris JA, Swenson CW, Uppal S, Kamdar N, Mahnert N, As-Sanie S, Morgan DM. Practice patterns and postoperative complications before and after US Food and Drug Administration safety communication on power morcellation. Am J Obstet Gynecol. 2016;214:e1-13.

Google Scholar 

Sagae S, Yamashita K, Ishioka S, Nishioka Y, Terasawa K, Mori M, et al. Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido. Japan Oncology. 2004;67:33–9.

PubMed  Google Scholar 

George S, Serrano C, Hensley ML, Ray-Coquard I. Soft tissue and uterine leiomyosarcoma. J Clin Oncol. 2018;36(2):144–50.

CAS  PubMed  Google Scholar 

Chantharasamee J, Wong K, Potivongsajarn P, Qorbani A, Motamed N, Brackert S, Cohen J, Chmielowski B, Kalbasi A, Rao J, Nelson S. Retrospective analysis of adjuvant treatment for localized, operable uterine leiomyosarcoma. Cancer Med. 2022;11(15):2906–12.

PubMed  PubMed Central  Google Scholar 

Ferrero A, Attianese D, Villa M. Chemotherapy and uterine sarcomas: a narrative review. Gynecol Pelvic Med. 2021;4:37.

Google Scholar 

Maccaroni E, Lunerti V, Agostinelli V, Giampieri R, Zepponi L, Pagliacci A, Berardi R. New insights into hormonal therapies in uterine sarcomas. Cancers. 2022;14:921. https://doi.org/10.3390/cancers14040921.

CAS  PubMed  PubMed Central  Google Scholar 

Hensley ML, Wathen JK, Maki RG, et al. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer. 2013;119(8):1555–61.